As of 2025-07-14, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.5x - 14.0x | 13.6x |
| Forward P/E multiples | 17.2x - 39.9x | 27.0x |
| Fair Price | (112.32) - (90.50) | (133.11) |
| Upside | -247.8% - -219.1% | -275.1% |
| Date | EV/EBITDA |